Amiloride
- Generic Name
- Amiloride
- Brand Names
- Midamor
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8ClN7O
- CAS Number
- 2609-46-3
- Unique Ingredient Identifier
- 7DZO8EB0Z3
- Background
A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
- Indication
For use as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension.
- Associated Conditions
- Ascites, Calcium Nephrolithiasis, Congestive Heart Failure (CHF), Hypertension, Hypokalemia, Metabolic Alkalosis, Polyuria
- Associated Therapies
- -
The Effect of Amiloride and Spironolactone in Healthy Persons
- Conditions
- High Blood Pressure
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2011-07-08
- Lead Sponsor
- Regional Hospital Holstebro
- Target Recruit Count
- 30
- Registration Number
- NCT00857909
- Locations
- 🇩🇰
Medical Research, Holstebro, Denmark
Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- VA Salt Lake City Health Care System
- Registration Number
- NCT00709137
- Locations
- 🇺🇸
VAMC SLC - George Wahlen VA, SLC, Utah, United States
Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2006-01-10
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 24
- Registration Number
- NCT00274391
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Registration Number
- NCT00004705
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.